secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001703057-24-000017
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera FY2023 revenue $38M (down 92% YoY), net loss $0.51/share
------------------------------------------------------------------

- Revenue fell to $38.0M from $485.4M in FY2022; research fees were $35.6M.
- Net loss of $146.4M ($0.51 basic & diluted EPS) vs net income of $158.5M in 2022.
- R&D expenses surged to $175.7M (up 63% YoY) on program and platform investments.
- Cumulative partner-initiated program starts reached 87; 13 molecules in clinic.
- Advanced two internal programs (ABCL635, ABCL575) into IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/0001703057-24-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305724000017/abcl-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001703057-24-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer